IDNA vs IXJ

Key Takeaways

• IDNA is a thematic ETF targeting companies benefiting from genomics, immunology, and bioengineering innovations, while IXJ provides broad exposure to the global healthcare sector.
• IDNA maintains a concentrated portfolio of approximately 50 holdings compared to IXJ’s more diversified 110+ holdings.
• Both ETFs are passively managed and focus exclusively on healthcare, but IDNA carries a higher expense ratio of 0.47% versus 0.38% for IXJ.
• IDNA offers higher-risk thematic exposure to innovative biopharma subsectors, whereas IXJ delivers broader large-cap healthcare stability across pharmaceuticals, services, and equipment.
• Structural differences in index methodology and concentration levels drive distinct risk-return profiles and sector rotation sensitivities for each fund.

Introduction

Investors seeking healthcare exposure often weigh specialized thematic strategies against broad sector funds. IDNA and IXJ both target healthcare equities yet pursue different objectives. IDNA emphasizes innovation in genomics and immunology, while IXJ tracks the wider global healthcare industry. The comparison helps investors evaluate concentrated thematic risk versus diversified sector allocation within the same overarching market segment.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The IDNA ETF seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. It holds approximately 50 securities focused on companies positioned to benefit from long-term advances in genomics, immunology, and bioengineering. The portfolio is heavily weighted toward health care, with nearly 100% allocation to that sector. Top holdings typically include firms such as Moderna, Bayer, and Regeneron Pharmaceuticals. The fund employs a passive, rules-based methodology with periodic rebalancing to maintain index alignment. Its expense ratio stands at 0.47%. IDNA is structured as an open-end fund listed on NYSE Arca, offering targeted exposure to innovative healthcare subsectors.

iShares Global Healthcare ETF (IXJ) Overview

The IXJ ETF tracks the S&P Global 1200 Health Care Sector Capped Index. It provides exposure to approximately 110 global healthcare companies across pharmaceuticals, biotechnology, medical devices, and healthcare services. The fund maintains a large-cap bias, with the majority of assets in developed-market equities. Representative top holdings include Eli Lilly, Johnson & Johnson, and AbbVie. IXJ follows a passive sampling approach with semi-annual rebalancing. Its expense ratio is 0.38%. The ETF is also an open-end fund listed on NYSE Arca and serves as a diversified vehicle for broad healthcare sector participation.

Industry and Thematic Backdrop

The healthcare sector continues to experience structural growth driven by aging populations, advances in biotechnology, and expanding global access to medical services. Regulatory developments around drug pricing and innovation incentives influence capital allocation across subsectors. Macroeconomic factors such as interest rate expectations and currency fluctuations affect multinational healthcare firms. Both thematic and broad healthcare strategies face risks from clinical trial outcomes, patent expirations, and geopolitical tensions affecting supply chains. Capital flows into healthcare often accelerate during periods of sector rotation favoring defensive growth areas.

Performance and Positioning Comparison

In recent market cycles, IDNA’s concentrated focus on genomics and immunology has produced greater volatility tied to innovation-driven earnings events and sector sentiment shifts. IXJ, with its broader holdings and large-cap emphasis, has demonstrated more stable relative positioning during periods of healthcare rotation. Performance differentials often reflect varying sensitivities to biotech-specific catalysts versus overall pharmaceutical and services earnings trends. The thematic fund’s higher concentration amplifies exposure to individual company developments, while the global sector fund benefits from diversification across multiple healthcare sub-industries.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking to compare funds like IDNA and IXJ can leverage these capabilities to refine their research process.

Tickeron AI Verdict

Based on structural characteristics including lower expense ratio, greater diversification, and broader sector coverage, Tickeron’s AI would currently assign a probabilistic preference to IXJ for investors prioritizing cost efficiency and risk-adjusted exposure within global healthcare. IDNA remains suitable for those seeking concentrated thematic exposure to genomics and immunology innovation, though its higher cost and concentration warrant careful consideration of risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations